Affordable Access

Publisher Website

Development and Validation of a Simultaneous Quantification Method of Ruxolitinib, Vismodegib, Olaparib, and Pazopanib in Human Plasma Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

Authors
  • Pressiat, Claire1, 2
  • Huynh, Huu-Hien1
  • Plé, Alain1, 2
  • Sauvageon, Hélène1, 2
  • Madelaine, Isabelle2
  • Chougnet, Cécile3
  • Le Maignan, Christine4
  • Mourah, Samia1, 5
  • Goldwirt, Lauriane1, 5
Type
Published Article
Journal
Therapeutic drug monitoring
Publication Date
May 31, 2018
Volume
40
Issue
3
Pages
337–343
Identifiers
DOI: 10.1097/FTD.0000000000000497
PMID: 29474275
Source
Medline
Language
English
License
Unknown

Abstract

A simple, rapid, and sensitive liquid chromatography coupled with tandem mass spectrometry method has been developed and validated for the quantification of ruxolitinib, olaparib, vismodegib, and pazopanib in human plasma. After a simple protein precipitation of plasma samples, the chromatographic separation was performed using an ultraperformance liquid chromatography system coupled with mass tandem spectrometry in a positive ionization mode. The mobile phase consisted of a gradient elution of 10-mmol/L formate ammonium buffer containing 0.1% (vol/vol) formic acid (phase A) and acetonitrile with 0.1% (vol/vol) formic acid (phase B) at a flow rate at 300 µL/min. Analysis time was 5.0 minutes per run, and all analytes and internal standards eluted within 1.5-1.73 minutes. The calibration curves were linear over the range from 10 to 2500 ng/mL for ruxolitinib and from 100 to 100,000 ng/mL for olaparib, vismodegib, and pazopanib with coefficients of correlation above 0.99 for all analytes. The intraday and interday coefficients of variation were below 14.26% and 14.81%, respectively, for lower concentration and below 9.94% and 6.37%, respectively, for higher concentration. Using liquid chromatography coupled with tandem mass spectrometry, we have developed and validated a simple and rapid assay for the simultaneous quantification of olaparib, vismodegib, pazopanib, and ruxolitinib in human plasma. This method is now part of our therapeutic drug monitoring service provision and is currently used clinically to manage patients prescribed these drugs.

Report this publication

Statistics

Seen <100 times